Literature DB >> 11160631

Signaling mechanisms for the selective vasoconstrictor effect of norbormide on the rat small arteries.

S Bova1, L Trevisi, L Cima, S Luciani, V Golovina, G Cargnelli.   

Abstract

Norbormide (NRB) is a selective vasoconstrictor agent of the rat small vessels. The mechanisms underlying the selective vasoconstrictor effect of NRB are unknown. To investigate whether phospholipase C (PLC) signaling pathway plays a role in NRB-induced vasoconstriction, we performed experiments in NRB-contracted tissues, namely, rat caudal arteries (RCA) and smooth muscle cells derived from rat mesenteric arteries (MVSMCs). An NRB-insensitive vessel, namely rat aorta (RA), served as a control tissue. In RCA and RA we measured either isometric tension or formation of inositol phosphates (IPs), the latter taken as an index of PLC activation. In MVSMCs, we measured intracellular free calcium concentration ([Ca2+]cyt). In the presence of external Ca2+, NRB (2-50 microM) stimulated IPs formation in RCA but not in RA, and increased [Ca2+]cyt in MVSMCs. In the absence of external Ca2+, NRB (50 microM) increased IPs formation in RCA but was unable to increase [Ca2+]cyt in MVSMCs. In RCA, in the presence of external Ca2+, NRB-induced contraction was inhibited by calphostin C (0.2-1 microM), an inhibitor of protein kinase C (PKC), and by SK&F 96365 (30 microM), an inhibitor of the store-operated calcium channels, but was poorly affected by verapamil, an L-type calcium channel blocker. However, verapamil was much more effective when external Ca2+ was substituted by Sr2+. These results suggest that NRB elicits its tissue and species-selective vasoconstrictor effect by stimulating PLC-PKC pathway and increasing Ca2+ influx through both verapamil-sensitive and -insensitive calcium channels. Ca2+ release from sarcoplasmic reticulum seems not involved in NRB vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160631

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Hydrogen peroxide induces a greater contraction in mesenteric arteries of spontaneously hypertensive rats through thromboxane A(2) production.

Authors:  Y J Gao; R M Lee
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

2.  Prostatic relaxation induced by loperamide is mediated through activation of opioid μ-2 receptors in vitro.

Authors:  Chih-Cheng Lu; Hsien-Hui Chung; Juei-Tang Cheng
Journal:  Exp Ther Med       Date:  2011-01-20       Impact factor: 2.447

3.  Opiate-induced constipation related to activation of small intestine opioid μ2-receptors.

Authors:  Wency Chen; Hsien-Hui Chung; Juei-Tang Cheng
Journal:  World J Gastroenterol       Date:  2012-03-28       Impact factor: 5.742

4.  Ca(2+) entry blocking and contractility promoting actions of norbormide in single rat caudal artery myocytes.

Authors:  Fabio Fusi; Simona Saponara; Giampietro Sgaragli; Gabriella Cargnelli; Sergio Bova
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

5.  Prostatic relaxation induced by loperamide is reduced in spontaneously hypertensive rats.

Authors:  Liang-Ming Lee; Chih-Cheng Lu; Hsien-Hui Chung; Juei-Tang Cheng
Journal:  ScientificWorldJournal       Date:  2012-05-03

6.  Reduction of blood pressure by store-operated calcium channel blockers.

Authors:  Yan-Jun Xu; Vijayan Elimban; Naranjan S Dhalla
Journal:  J Cell Mol Med       Date:  2015-10-16       Impact factor: 5.310

7.  Synthesis and Biological Characterization of a New Norbormide Derived Bodipy FL-Conjugated Fluorescent Probe for Cell Imaging.

Authors:  Claudio D'Amore; Genny Orso; Alessia Forgiarini; Giulio Ceolotto; David Rennison; Giovanni Ribaudo; Morgan Jay-Smith; Brian Hopkins; Margaret A Brimble; Sergio Bova
Journal:  Front Pharmacol       Date:  2018-09-25       Impact factor: 5.810

8.  The Selective Rat Toxicant Norbormide Blocks KATP Channels in Smooth Muscle Cells But Not in Insulin-Secreting Cells.

Authors:  Simona Saponara; Fabio Fusi; Ottavia Spiga; Alfonso Trezza; Brian Hopkins; Margaret A Brimble; David Rennison; Sergio Bova
Journal:  Front Pharmacol       Date:  2019-05-23       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.